SpectraCure (SPEC) investor relations material

Executive summary

• Achieved significant clinical progress in 2025, with promising results in both recurrent and primary localized prostate cancer studies.

• Expanded clinical collaborations and secured regulatory approvals in Europe, positioning for phase 3 trials.

• Focus for 2026 is on completing phase 2 studies and preparing for phase 3, while accelerating patient recruitment and securing financing.

Financial highlights

• Full-year net loss after tax was -56,079 TSEK, compared to -23,004 TSEK in 2024.

• Q4 net loss after tax was -7,556 TSEK, compared to -4,650 TSEK in Q4 2024.

• Result per share for the year was -0.20 SEK, compared to -0.17 SEK in 2024.

• Cash flow from operating activities for the year was -24,026 TSEK; cash and cash equivalents at year-end were 13,525 TSEK.

• A non-recurring impairment of 27,588 TSEK was recorded for older capitalized development projects.

Outlook and guidance

• Main priorities for 2026 are to complete phase 2 of the recurrent prostate cancer study and prepare for phase 3.

• Efforts will focus on accelerating clinical studies and securing additional funding.

• Management is confident in the ability to raise necessary capital and increase the pace of clinical development.